---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-142950"
form_type: "8-K"
ticker: "COYA"
cik: "0001835022"
company_name: "Coya Therapeutics, Inc."
filed_at: "2024-05-20T23:59:59+00:00"
generated_at: "2026-06-01T13:15:06.035248+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Coya receives $5M strategic investment from ADDF for COYA 302 FTD trial

## Summary
- ADDF purchased 603,136 shares at $8.29/share for $5M gross proceeds in private placement.
- Funds will support COYA 302 development for frontotemporal dementia (FTD) Phase 2 trial.
- ADDF, focused on Alzheimer's and related dementias, backs combination therapy approach.
- Registration statement for resale of shares to be filed within 30 days and effective within 75 days.

## SEC filing metadata
- accession: 0001193125-24-142950
- form_type: 8-K
- ticker: COYA
- cik: 0001835022
- company_name: Coya Therapeutics, Inc.
- filed_at: 2024-05-20T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 1.01, 3.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1835022/000119312524142950/0001193125-24-142950-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1835022/000119312524142950/d820823d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-142950
- JSON: https://secwatch.observer/filing/0001193125-24-142950.json
- Plain text: https://secwatch.observer/filing/0001193125-24-142950.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.